Revenue for the year ended December 31, 2025, increased by 957% to $1.142 million, up from $108,000 in 2024, primarily due to the acquisition of Evoke Neuroscience. Net loss and comprehensive loss for 2025 was $(19.882) million, an increase from $(10.460) million in 2024. Operating expenses decreased by 6.5% to $9.501 million in 2025 from $10.162 million in 2024, mainly due to reduced research and development and selling and marketing expenses. General and administrative expenses increased by 13% to $6.968 million in 2025, largely due to D&O insurance costs post-Merger and accrued fees from an Equity Line of Credit cancellation. The company incurred a significant 'Change in derivative fair value' loss of $(9.369) million in 2025, compared to $(156,000) in 2024. Cash used in operating activities increased by 33% to $(8.194) million in 2025 from $(6.155) million in 2024. The acquisition of Evoke Neuroscience Inc. on April 30, 2025, for $6.221 million (consisting of $3.000 million cash and 857,142 common shares valued at $2.743 million, plus a $478,000 earn-out liability) significantly expanded business operations and headcount. As of December 31, 2025, the company had an accumulated deficit of $111.615 million and negative cash flows from operating activities of $8.194 million, raising substantial doubt about its ability to continue as a going concern. The company identified material weaknesses in internal control over financial reporting related to inadequate Information Technology General Controls (ITGC) and lack of segregation of duties. Subsequent to December 31, 2025, the company raised $150,000 from warrant exercises and $2.250 million from an initial private placement tranche, with an option for investors to purchase up to an additional $18.000 million. An At-the-Market (ATM) offering program was established on February 3, 2026, to sell up to $7.434 million in common stock. A warrant cancellation and exchange agreement on December 16, 2025, resulted in the exchange of 800,000 warrants (exercise prices $3.50 and $4.00) for new warrants at an exercise price of $0.50 per share, leading to a deemed dividend of $239,000.